State of Delaware - FY24 Budget  It is probable that the COVID-19 pandemic will have an impact on health care costs. In performing this analysis to develop health care cost estimates for GHIP, we have not explicitly reflected adjustments due to the impact of COVID-19. Due to the high degree of uncertainty associated with this pandemic, results may van							
It is probable that the COVID-19 pandemic will have an impact on health care costs. In performing this analysis to develop health care cost estimates for GHIP, re have not explicitly reflected adjustments due to the impact of COVID-19. Due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.							

## State of Delaware

FY24 Budget<sup>1</sup>

August 2023

	Estimated FY 2024						
	as of August 2023 <sup>1</sup>						
,							
Balance Forward <sup>2</sup>	\$	58,840,987					
Operating Revenues							
Premium Contributions							
Highmark	\$	783,334,287	65.05%				
Aetna	\$	203,489,467	16.90%				
Total Premium Contributions	\$	986,823,754					
Other Revenues							
Medicare Retiree Prescription Subsidy Program (EGWP) <sup>3</sup>	\$	938,720	0.08%				
Federal Reinsurance <sup>3</sup>	\$	25,038,872	2.08%				
Prescription Drug Rebates - Commercial <sup>4</sup>	\$	79,783,719	6.63%				
Prescription Drug Rebates - EGWP <sup>4</sup>	\$	60,148,247	4.99%				
Prescription True Up/Yr End Recon Pymts <sup>5</sup>	s	13,466,470	1.12%				
Medicare Part D - Coverage Gap Discount <sup>3</sup>	s	30,765,967	2.55%				
Participating Group Fees <sup>6</sup>	s	7,315,468	0.61%				
Other Revenues	\$	7,313,408	0.00%				
Total Other Revenues	\$	217,457,462	0.0070				
Total Operating Revenues	S	1,204,281,215					
Operating Expenses		-,,					
Claims <sup>7</sup>							
Highmark	\$	621,835,307	49.34%				
Aetna	\$	185,517,442	14.72%				
CVS (non-Plan D)	\$	208,590,040	16.55%				
CVS (Plan D) Total Claims	\$	197,712,114 1,213,654,903	15.69%				
Other Expenses							
Program Fees and Costs (Vendor ASO Fees)	s	39.812.591	3.16%				
Office Expenses	\$	3,719,461	0.30%				
Employee Assistance	\$	479,742	0.04%				
Data Warehouse	\$	722,592	0.06%				
Consultant Fees	\$	1,500,000	0.12%				
COBRA Fees	\$	90,820	0.01%				
ACA Fees	\$	365,828	0.03%				
Total Other Expenses	\$	46,691,033					
Total Operating Expenses	s	1,260,345,935					
Net Income	S	(56,064,720)					
Fund Equity Balance	s	2,776,267					
Claim Liability	s	72,400,000					
Minimum Reserve	\$	28,800,000					
GHIP Surplus (After Reserves)	s	(98,423,733)					
WTW Budget (SM) <sup>8</sup>	s	1,041.0					
······ suage (#!!)	J.						
Average Members  Based on claims experience for the period 7/1/2022 - 6/30/2023; headco		132,432					

<sup>&</sup>lt;sup>1</sup> Based on claims experience for the period 7/1/2022 - 6/30/2023; headcounts reflect July 2023 open enrollment with 1% growth during FY24; 6% medical (3% Medicfill) and 9% Rx trend; EGWP revenues and prescription drug rebates based on the period revenues will be paid

Note: It is evident that the COVID-19 pandemic will have an impact on health care costs. We have used available information and reasonable estimation techniques to develop health care cost estimates for the GHIP that reflect the impact of COVID-19. However due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.

<sup>&</sup>lt;sup>2</sup> Balance Forward reflects actual balance as of June 2023 Fund Equity Report

<sup>&</sup>lt;sup>3</sup> EGWP revenue reflects actual revenues received through June 2023; remaining revenues through CY23 and CY24 based on projected PMPM payments provided by CVS

<sup>&</sup>lt;sup>4</sup> FY24 rebates based on when rebates will be received by GHIP; assumes 60 day lag on CVS rebate payments

 $<sup>^{\</sup>rm 5}$  Reflects CY22 federal reinsurance true-up payment expected to be received in January 2024

<sup>&</sup>lt;sup>6</sup> Participating Group Fees shown for FY24 are estimated based on FY23 fees and assumed FY24 headcounts and premiums

<sup>&</sup>lt;sup>7</sup>FY24 projected claims reflect CVS market check contract improvements

<sup>8</sup> WTW Budget represents the FY24 projected expenses based on assumptions approved by the SEBC, updated with claims data through June 2023 and July open enrollment; WTW Budget equals total operating expenses, less ACA and consultant fees, less total other revenues

## State of Delaware

FY24 Budget1

August 2023

•				4	5	6	7	8	9	10	11	12	
Operating Revenues	July	August	September	October	November	December	January	February	March	April	May	June	TOTAL
Premium Contributions													
Highmark	\$ 62,475,578	\$ 65,266,165					65,591,684 \$	65,591,684	\$ 65,591,684	\$ 65,755,052			783,334,287
Aetna	\$ 16,214,018	\$ 16,955,820	\$ 16,955,820		\$ 16,998,051 \$		17,040,388 \$	17,040,388	\$ 17,040,388	\$ 17,082,830			203,489,467
Total Premium Contributions	\$ 78,689,596	\$ 82,221,985	\$ 82,221,985	\$ 82,426,774	\$ 82,426,774 \$	82,426,774 \$	82,632,073 \$	82,632,073	\$ 82,632,073	\$ 82,837,883	\$ 82,837,883	\$ 82,837,883 \$	986,823,754
Other Revenues													
Medicare Retiree Prescription Subsidy Program (EGWP) <sup>2</sup>	\$ 4.835	\$ (95.393)	\$ (95,393)	\$ (143,446)	\$ (143,446) \$	(143,446) \$	258.846 \$	258.846	\$ 258.846	\$ 259.490	\$ 259,490	\$ 259.490 \$	938.720
Federal Reinsurance <sup>2</sup>	\$ 1,933,426	\$ 1.933.426	\$ 1.933.426		\$ 1,938,241		2.234.529 \$	2.234.529	\$ 2.234.529	\$ 2.240.095			25.038.872
Prescription Drug Rebates - Commercial <sup>3</sup>	\$ 1,000,120	\$ 18.905.075	, , , , , ,	, ,,,,,	\$ 19.946.440 \$	, , , , , , , ,	- \$	20,234,251		\$ -	\$ 20.697.953		79,783,719
Prescription Drug Rebates - EGWP <sup>3</sup>	s -	\$ 15,013,124		7	\$ 14.806.609		- S	14.931.948		\$ -	\$ 15.396.565		60,148,247
Prescription True Up / Yr End Recon Pymts <sup>4</sup>	\$ -			7	\$ - 5		13.466.470 \$	,,.	•	\$ -	\$ -	s - s	13.466.470
Medicare Part D - Coverage Gap Discount <sup>2</sup>	s -	•	\$ -		· .		10,400,470 \$		\$ 9.446.543		\$ -	\$ 4.557.489 \$	30.765.967
Participating Group Fees <sup>5</sup>	\$ 607.349	\$ 607,349	\$ 607,349		\$ 608,862		610,379 \$	610,379		\$ 611,899	7		7,315,468
Other Revenues	\$ 607,349	\$ 607,349	\$ 607,349		\$ 000,002		010,379 \$	610,379	\$ 610,379	\$ 511,099	\$ 611,099	\$ - \$	7,313,400
Total Other Revenues	\$ 2.545.610				\$ 37,156,706		16,570,223 \$					Ψ Ψ	217,457,462
Total Other Revenues	ψ 2,545,010	Ψ 30,000,002	ψ 2,440,002	ψ 3,302,300	Ψ 37,130,700 ξ	11,010,007	10,570,225 ψ	00,200,002	Ψ 12,000,201	Ψ 5,111,404	9 33,200,002	Ψ 7,000,373 Ψ	211,401,402
Total Operating Revenues	\$ 81,235,207	\$ 118,585,567	\$ 84.667.367	\$ 92.379.337	\$ 119,583,480 \$	94,043,461 \$	99.202.296 \$	120,902,024	\$ 95,182,369	\$ 85.949.366	\$ 122,043,885	\$ 90,506,855 \$	1,204,281,215
Total operating Revenues	V 01,200,201	¥ 110,000,001	<b>V</b> 04,007,007	02,010,001	* 110,000,100	04,040,401	00,202,200	120,002,024	¥ 00,102,000	<b>V</b> 00,040,000	122,010,000	\$ 00,000,000 \$	1,204,201,210
Operating Expenses	July	August	September	October	November	December	January	February	March	April	May	June	TOTAL
Claims <sup>6</sup>													
Highmark	\$ 45,878,756	\$ 57,348,445	\$ 45,878,756	\$ 54,555,334	\$ 43,644,267 \$	43,644,267 \$	63,351,945 \$	50,681,556	\$ 50,681,556	\$ 63,911,701	\$ 51,129,361	\$ 51,129,361 \$	621,835,307
Aetna	\$ 13,687,401				\$ 13,020,767 \$	16,275,959 \$	15,120,262 \$	15,120,262	\$ 18,900,327	\$ 15,253,859	\$ 19,067,324	\$ 15,253,859 \$	185,517,442
CVS (non-Plan D)	\$ 16,171,545	\$ 16,171,545	\$ 16,171,545	\$ 16,762,156	\$ 16,762,156 \$		17,519,704 \$	17,519,704	\$ 17,519,704	\$ 19,076,609	\$ 19,076,609	\$ 19,076,609 \$	208,590,040
CVS (Plan D)	\$ 15,320,283		\$ 15,320,283		\$ 15,786,441 \$		16,632,145 \$	16,632,145	\$ 16,632,145	\$ 18,165,169			197,712,114
Total Claims	\$ 91,057,985	\$ 102,527,674	\$ 94,479,835	\$ 100,124,698	\$ 89,213,631 \$	92,468,823 \$	112,624,055 \$	99,953,666	\$ 103,733,732	\$ 116,407,339	\$ 107,438,464	\$ 103,624,999 \$	1,213,654,903
Other Expenses													
	\$ 3.307.357	\$ 3.307.357	\$ 3,307,357	\$ 3.314.252	\$ 3,314,252 \$	3.314.252 \$	3.321.163	3.321.163	\$ 3,321,163	\$ 3.328.092	\$ 3.328.092	\$ 3.328.092 \$	39.812.591
Program Fees and Costs (Vendor ASO Fees) Office Expenses	\$ 3,307,357						309,955 \$						3,719,461
Employee Assistance	\$ 39,979						39.979						479.742
Data Warehouse	\$ 59,979						60.216						722.592
Consultant Fees	\$ 125,000						125,000 \$			\$ 125,000			1,500,000
COBRA Fees	\$ 7.568						7.568 \$	7.568	\$ 7.568	\$ 7.568			90.820
ACA Fees	\$ 365.828		\$ -		\$ - 5		- S	-	\$ -	\$ -	\$ -	s - s	365.828
Total Other Expenses	\$ 4,215,902		\$ 3,850,075	\$ 3,856,969			3,863,881 \$	3,863,881	\$ 3,863,881	\$ 3,870,810	\$ 3,870,810	\$ 3,870,810 \$	46,691,033
Total Operating Expenses	\$ 95,273,887	\$ 106,377,749	\$ 98,329,910	\$ 103,981,668	\$ 93,070,601	96,325,793 \$	116,487,936 \$	103,817,547	\$ 107,597,613	\$ 120,278,149	\$ 111,309,274	\$ 107,495,809 \$	1,260,345,935
Net Income	(\$14,038,681)	\$12,207,818	(\$13,662,543)	(\$11,602,331)	\$26,512,879	(\$2,282,332)	(\$17,285,641)	\$17,084,477	(\$12,415,244)	(\$34,328,783)	\$10,734,611	(\$16,988,953)	(\$56,064,720)
Amount Carried Forward <sup>7</sup>	\$ 58,840,987	\$ 44,802,306	\$ 57,010,125	\$ 43,347,582	\$ 31,745,251	58,258,131 \$	55,975,799 \$	38,690,158	\$ 55,774,635	\$ 43,359,392	\$ 9,030,609	\$ 19,765,220 \$	58,840,987
Fund Equity Balance	\$ 44,802,306	\$ 57,010,125	\$ 43,347,582	\$ 31,745,251	\$ 58,258,131 \$	55,975,799 \$	38,690,158 \$	55,774,635	\$ 43,359,392	\$ 9,030,609	\$ 19,765,220	\$ 2,776,267 \$	2,776,267
								•					
GHIP Surplus (After Reserves)	(\$56,397,694)	(\$44,189,875)	(\$57,852,418)	(\$69,454,749)	(\$42,941,869)	(\$45,224,201)	(\$62,509,842)	(\$45,425,365)	(\$57,840,608)	(\$92,169,391)	(\$81,434,780)	(\$98,423,733)	(\$98,423,733)

Based on claims experience for the period 7/1/2022 - 6/30/2023; headcounts reflect July 2023 open enrollment with 1% growth during FY24; 6% medical (3% Medicfill) and 9% Rx trend; EGWP revenues and prescription drug rebates based on the period revenues will be paid

<sup>&</sup>lt;sup>2</sup> EGWP revenue reflects actual revenues received through June 2023; remaining revenues through CY23 and CY24 based on projected PMPM payments provided by CVS

<sup>&</sup>lt;sup>3</sup> FY24 rebates based on when rebates will be received by GHIP; assumes 60 day lag on CVS rebate payments

<sup>&</sup>lt;sup>4</sup> Reflects CY22 federal reinsurance true-up payment expected to be received in January 2024

<sup>&</sup>lt;sup>5</sup> Participating Group Fees shown for FY24 are estimated based on FY23 fees and assumed FY24 headcounts and premiums

<sup>&</sup>lt;sup>6</sup> FY24 projected claims reflect CVS market check contract improvements

Balance Forward reflects actual balance as of June 2023 Fund Equity Report

Note: It is evident that the COVID-19 pandemic will have an impact on health care costs. We have used available information and reasonable estimates for the GHIP that reflect the impact of COVID-19. However due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.

M	1	2	3	4	5	6	7	8	9	10	11	12	
Operating Revenues	July	August	September	October	November	December	January	February	March	April	Mav	June	TOTAL
-													
Premium Contributions													
Highmark	\$ 62,475,578			258,436,632		\$ 389,294,076 \$				651,824,182 \$	717,579,234		783,334,287
Aetna	\$ 16,214,018			67,123,709		\$ 101,119,812 \$			152,240,976 \$	169,323,806 \$	186,406,637		203,489,467
Total Premium Contributions	\$ 78,689,596	\$ 160,911,582	\$ 243,133,567	325,560,341	\$ 407,987,115	\$ 490,413,889 \$	573,045,961	\$ 655,678,034	738,310,106 \$	821,147,989 \$	903,985,871	\$ 986,823,754 \$	986,823,754
Other Revenues													
Medicare Retiree Prescription Subsidy Program (EGWP) <sup>2</sup>	\$ 4,835	\$ (90,558)	\$ (185,951) \$	(329,397)	\$ (472,843)	\$ (616,289) \$	(357,443)	\$ (98,597)	160,249 \$	419,739 \$	679,229	\$ 938,720 \$	938,720
Federal Reinsurance <sup>2</sup>	\$ 1,933,426	\$ 3.866.851	\$ 5.800.277 \$			\$ 11.615.001 \$	13.849.530			20.558.683 \$	22.798.777		25.038.872
Prescription Drug Rebates - Commercial <sup>3</sup>	\$ -	\$ 18.905.075				\$ 38.851.515 \$	38.851.515			59.085.766 \$	79.783.719		79,783,719
Prescription Drug Rebates - EGWP <sup>3</sup>	\$ -	\$ 15,013,124			,	\$ 29,819,734 \$				44.751.682 \$	60.148.247	,,	60.148.247
Prescription True Up / Yr End Recon Pymts <sup>4</sup>	\$ -		\$ - 5			s - s				13,466,470 \$	13.466.470		13,466,470
Medicare Part D - Coverage Gap Discount <sup>2</sup>	s -	\$ -	S - 5	7.548.906	\$ 7,548,906	\$ 16,761,935 \$	16,761,935			26,208,478 \$	26,208,478	\$ 30,765,967 \$	30,765,967
Participating Group Fees <sup>5</sup>	\$ 607.349	\$ 1,214,699	\$ 1.822.048 \$	2,430,911		\$ 3,648,635 \$	4.259.014			6.091.670 \$	6.703.569	\$ 7.315.468 \$	7.315.468
Other Revenues	\$ -	\$ -	\$ - 5			\$ - \$			- \$	- \$	- :		-
Total Other Revenues	\$ 2,545,610	\$ 38,909,192	\$ 41,354,574	51,307,138	\$ 88,463,844	\$ 100,080,531 \$	116,650,754	\$ 154,920,706	167,471,002 \$	170,582,486 \$	209,788,489	\$ 217,457,462 \$	217,457,462
Total Operating Revenues	\$ 81,235,207	\$ 199,820,774	\$ 284,488,141	376,867,478	\$ 496,450,959	\$ 590,494,420 \$	689,696,715	\$ 810,598,739	905,781,109 \$	991,730,475 \$	1,113,774,360	\$ 1,204,281,215 \$	1,204,281,215
0			0	0.1.1			•	F-1					T0741
Operating Expenses	July	August	September	<u>October</u>	<u>November</u>	<u>December</u>	<u>January</u>	<u>February</u>	<u>March</u>	April	Mav	June	TOTAL
6													
Claims <sup>6</sup>	A 45 070 750		A 440 405 050 4	000 004 000	0.47.005.550	A 000 040 007 A	054 004 770		455.004.004.0	540 570 505 0	570 705 040	004 005 007	004 005 007
Highmark Aetna	\$ 45,878,756 \$ 13.687,401			203,661,292 57,504,822		\$ 290,949,827 \$ \$ 86,801,549 \$				519,576,585 \$ 151,196,259 \$	570,705,946 170,263,583		621,835,307 185,517,442
CVS (non-Plan D)	\$ 16,171,545			65.276.789		\$ 98,801,101 \$	116,320,805	\$ 133,840,508	155,942,399 \$	170,436,822 \$	189,513,431		208,590,040
CVS (Plan D)	\$ 15,320,283			61,747,289		\$ 93,320,172 \$	109,952,316		143,216,605 \$	161,381,775 \$	179,546,944		197,712,114
Total Claims	\$ 91.057.985	\$ 193.585.659		388.190.193	\$ 477,403,824	\$ 569.872.647 \$	682.496.703		886.184.101 \$	1.002.591.440 \$	1.110.029.904	\$ 1.213.654.903 \$	1.213.654.903
Total Claims	\$ 91,057,965	\$ 193,565,659	\$ 200,000,494	300,190,193	\$ 477,403,024	\$ 509,072,047 \$	002,490,703	\$ 762,450,369	000,104,101 \$	1,002,591,440 \$	1,110,029,904	\$ 1,213,054,903 \$	1,213,054,903
Other Expenses													
Program Fees and Costs (Vendor ASO Fees)	\$ 3,307,357	\$ 6,614,714	\$ 9,922,071 \$	13,236,323	\$ 16,550,574	\$ 19,864,826 \$	23,185,989	\$ 26,507,152 \$	29,828,315 \$	33,156,407 \$	36,484,499	\$ 39,812,591 \$	39,812,591
Office Expenses	\$ 309,955			1,239,820			2,169,685			3,099,551 \$	3,409,506		3,719,461
Employee Assistance	\$ 39,979					\$ 239,871 \$	279,850			399,785 \$	439,764		479,742
Data Warehouse	\$ 60,216									602,160 \$	662,376		722,592
Consultant Fees	\$ 125,000					\$ 750,000 \$				1,250,000 \$	1,375,000		1,500,000
COBRA Fees	\$ 7,568									75,683 \$	83,251		90,820
ACA Fees	\$ 365,828					\$ 365,828 \$	365,828			365,828 \$	365,828		365,828
Total Other Expenses	\$ 4,215,902	\$ 8,065,977	\$ 11,916,052 \$	15,773,022	\$ 19,629,991	\$ 23,486,960 \$	27,350,841	\$ 31,214,722	35,078,603 \$	38,949,413 \$	42,820,223	\$ 46,691,033 \$	46,691,033
Total Operating Expenses	\$ 95,273,887	\$ 201,651,636	\$ 299.981.547	403.963.214	\$ 497.033.815	\$ 593,359,608 \$	709.847.544	\$ 813,665,091	921,262,704 \$	1,041,540,853 \$	1,152,850,127	\$ 1,260,345,935 \$	1.260.345.935
	, 00,2.0,007	- 201,001,000	- 200,00.,047		,000,010	ψ σου,σου,σου ψ		. 0.0,000,001	,202,.0-7	.,,0-0,000	.,102,000,121	- 1,200,010,000	.,200,040,000
Net Income	\$ (14,038,681)	\$ (1,830,862)	\$ (15,493,405) \$	(27,095,736)	\$ (582,856)	\$ (2,865,188) \$	(20,150,829)	\$ (3,066,352) \$	(15,481,595) \$	(49,810,378) \$	(39,075,767)	\$ (56,064,720) \$	(56,064,720)
									ì				
Amount Carried Forward <sup>7</sup>	\$ 58,840,987	\$ 58,840,987	\$ 58,840,987	58,840,987	\$ 58,840,987	\$ 58,840,987 \$	58,840,987	\$ 58,840,987	58,840,987 \$	58,840,987 \$	58,840,987	\$ 58,840,987 \$	58,840,987
Fund Equity Balance	\$ 44,802,306	\$ 57,010,125	\$ 43,347,582	31,745,251	\$ 58,258,131	\$ 55,975,799 \$	38,690,158	\$ 55,774,635	43,359,392 \$	9,030,609 \$	19,765,220	\$ 2,776,267 \$	2,776,267
GHIP Surplus (After Reserves)	(\$56,397,694)	(\$44,189,875)	(\$57,852,418)	(\$69,454,749)	(\$42,941,869)	(\$45,224,201)	(\$62,509,842)	(\$45,425,365)	(\$57,840,608)	(\$92,169,391)	(\$81,434,780)	(\$98,423,733)	(\$98,423,733)

<sup>&</sup>lt;sup>1</sup> Based on claims experience for the period 7/1/2022 - 6/30/2023; headcounts reflect July 2023 open enrollment with 1% growth during FY24; 6% medical (3% Medicfill) and 9% Rx trend; EGWP revenues and prescription drug rebates based on the period revenues will be paid <sup>2</sup> EGWP revenue reflects actual revenues received through June 2023; remaining revenues through CY23 and CY24 based on projected PMPM payments provided by CVS

<sup>&</sup>lt;sup>3</sup> FY24 rebates based on when rebates will be received by GHIP; assumes 60 day lag on CVS rebate payments

<sup>4</sup> Reflects CY22 federal reinsurance true-up payment expected to be received in January 2024
5 Participating Group Fees shown for FY24 are estimated based on FY23 fees and assumed FY24 headcounts and premiums
6 FY24 projected claims reflect CVS market check contract improvements

Balance Forward reflects actual balance as of June 2023 Fund Equity Report

Note: It is evident that the COVID-19 pandemic will have an impact on health care costs. We have used available information and reasonable estimation techniques to develop health care cost estimates for the GHIP that reflect the impact of COVID-19. However due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.